• Contraindications
    • Patients with hypersensitivity to GnRH agonists or any of the excipients in LUPRON DEPOT.
    • Women who are or may become pregnant.

    Reference:
    LUPRON DEPOT 7.5 mg for
    1-month, 22.5 mg for
    3-month, 30 mg for 4-month,
    and 45 mg for 6-month [package insert].

  • Before Starting
    • Hyperglycemia and increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically in men receiving a GnRH agonist and manage hyperglycemia or diabetes.
    • An increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists in men, although the risk appears low. Evaluate the risks carefully, including cardiovascular risk factors, when determining prostate cancer treatment. Patients receiving a GnRH agonist should be monitored for signs and symptoms of cardiovascular disease and managed appropriately.
    • Androgen deprivation therapy (ADT) may prolong the QT/QTc interval. Consideration should be given to whether the benefits of ADT outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Correct electrolyte abnormalities and consider periodic monitoring of electrocardiograms and electrolytes.
    • Postmarketing reports of convulsions have been observed in patients on leuprolide acetate therapy, including patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications associated with convulsions, such as bupropion and SSRIs. Convulsions have also been reported in the absence of any of the conditions mentioned above.

    Reference:
    LUPRON DEPOT 7.5 mg for
    1-month, 22.5 mg for
    3-month, 30 mg for 4-month, and 45 mg for 6-month [package insert].

  • What Your
    Patients Can Expect
    • LUPRON DEPOT causes an initial increase in serum testosterone (~50% above baseline) during the first few weeks of treatment. This initial increase can cause:
      • Transient worsening of symptoms, or additional signs and symptoms of prostate cancer.
      • Temporary increase in bone pain in a small number of patients, which can be managed symptomatically.
      • Isolated cases of ureteral obstruction and spinal cord compression, which may contribute to paralysis with or without fatal complications. Observe patients with vertebral metastasis and/or urinary tract obstruction closely.
    • Periodic monitoring of serum testosterone and PSA levels is recommended.
    • LUPRON DEPOT may cause impotence.

    Reference:
    LUPRON DEPOT 7.5 mg for
    1-month, 22.5 mg for
    3-month, 30 mg for 4-month, and 45 mg for 6-month [package insert].

  • Side Effects
    • In controlled clinical trials of advanced prostatic cancer patients receiving LUPRON DEPOT, the following adverse events occurred
      in >10% of patients:
      • LUPRON DEPOT 7.5 mg for 1-month administration: hot flashes/sweats, general pain, edema, urinary disorders, GI disorders, and respiratory disorders.
      • LUPRON DEPOT 22.5 mg for 3-month administration: hot flashes/sweats, general pain, testicular atrophy, GI disorders, urinary disorders, injection site reactions, and joint disorders.
      • LUPRON DEPOT 30 mg for 4-month administration: hot flashes/sweats, injection site reactions, general pain, edema, urinary disorders, joint disorders, GI disorders, asthenia, flu syndrome, skin reactions, and headache.
      • LUPRON DEPOT 45 mg for 6-month administration: hot flush/flushing, upper respiratory tract infection/influenza-like illness, injection site pain/discomfort, and fatigue/lethargy.

    Reference:
    LUPRON DEPOT 7.5 mg for
    1-month, 22.5 mg for
    3-month, 30 mg for 4-month, and 45 mg for 6-month [package insert].

  • Helpful Resources

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

    If your patients cannot afford their medication, contact www.pparx.org for assistance.

    View the full Prescribing Information for LUPRON
    DEPOT at http://www.rxabbvie.com/pdf/
    lupronuro_pi.pdf
    .

    Reference:
    LUPRON DEPOT 7.5 mg for
    1-month, 22.5 mg for
    3-month, 30 mg for 4-month, and 45 mg for 6-month [package insert].

Print
Safety Facts
  • LUPRON DEPOT 7.5 mg for 1-month, 22.5 mg for
    3-month, 30 mg for 4-month, and 45 mg for
    6-month administration are indicated for the palliative treatment of advanced prostatic cancer.
  • LUPRON DEPOT is a gonadotropin-releasing hormone (GnRH) agonist administered as a single intramuscular injection under the supervision of a physician.

Reference:
LUPRON DEPOT 7.5 mg for 1-month, 22.5 mg for
3-month, 30 mg for 4-month, and 45 mg for
6-month [package insert].

Lupron Depot® (leuprolide acetate for depot suspension) | AbbVie Inc. supports the urology community with sponsorships, speakers and research.AbbVie and Lupron Depot Support
the Urology Community

Expanding knowledge and enhancing expertise
for healthcare professionals

AbbVie is proud to partner with and support professional organizations and initiatives that support and advance the field of urology and the study of advanced prostate cancer.


Urology speaker programs—peers sharing knowledge with patients in mind

AbbVie partners with key opinion leaders in urology to offer speaking engagements on how a holistic approach to patients’ health and well-being can benefit their advanced prostate cancer management.

To find out more about upcoming events, contact your AbbVie Representative.


Supporting your practice through professional organizations

The websites and information resources listed are not the property of AbbVie Inc. AbbVie Inc. does not assure the accuracy or timeliness of the information, and provides these references for your convenience only.

AbbVie is a corporate partner with the American Association of Clinical Urologists (AACU), which advocates for the best interests of urology patients and practices. The AACU works with the government on behalf of urologists to advance suitable laws, regulations, and health policies, and it coaches urologists on effective communications strategies.

The AUA promotes the highest standards of urological clinical care through education, research, and policy initiatives. AbbVie/Lupron Depot is a Premier Sponsor of the AUA as well as its Western, South East, South Central, and North Central Sections.

AbbVie is also a partner with AUACodingToday. Through our support, AbbVie recognizes the ever-increasing need for practice efficiency resources. The AUACodingToday website allows physician practices to get answers to their coding questions from a single source, helping them to bill accurately and efficiently.

LUGPA is the premier US association representing large urology practices. As a Premier Sponsor, AbbVie and Lupron Depot support their efforts to provide urological surgeons with access to the best resources, technology, and management for high-quality, efficient, and cost-effective care.

SUNA is dedicated to excellence in the care of patients with urological health concerns, with an emphasis on clinical practice, research, and education. AbbVie and Lupron Depot have supported them through the years by sponsoring specific programs and providing speakers at SUNA events.

ZERO is a patient advocacy organization dedicated to reducing, alleviating and eventually ending prostate cancer. AbbVie is proud to be the Premier Partner of its nationwide race and event series, the ZERO Prostate Cancer Challenge. Events in more than 30 cities across the country raise awareness and funds for free testing and research.

CaPSURE—collecting data from thousands to help thousands more

CaPSURE, or the Cancer of the Prostate Strategic Urologic Research Endeavor, is an ongoing longitudinal, observational study of more than 14,300 men with prostate cancer. AbbVie is currently the sole sponsor. The study data, which has been collected at 65 clinical practices throughout the US since 1995, has expanded our knowledge of risk prediction, diagnostic trends, treatment patterns, outcomes, and quality of life. More than 125 peer-reviewed articles have been published in journals based on CaPSURE data, yielding key insights that have advanced knowledge and treatment of prostate cancer.

CaPSURE is a trademark of the University of California, San Francisco.